Trial reportAdvances in therapy2021
Citicoline and Vitamin B
Trial report in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Do Nutrients and Nutraceuticals Play a Role in Diabetic Retinopathy? A Systematic Review.Nutrients · 2022Pooled it
- Citicoline May Effectively Reduce Hard Exudates in Diabetic Retinopathy.Biomedicines · 2025Article
- Neuronal Degeneration and Glial Activation in the Absence of Vascular Changes in Human Retinas of Patients With Diabetes.Investigative ophthalmology & visual science · 2025Article
- Targeting Senescence, Oxidative Stress, and Inflammation: Quercetin-Based Strategies for Ocular Diseases in Older Adults.Clinical interventions in aging · 2025Review
- Translational Research and Therapies for Neuroprotection and Regeneration of the Optic Nerve and Retina: A Narrative Review.International journal of molecular sciences · 2024Review
- Serum glial fibrillary acidic protein and neurofilament light chain as biomarkers of retinal neurodysfunction in early diabetic retinopathy: results of the EUROCONDOR study.Acta diabetologica · 2023Article
- The Role of Citicoline and Coenzyme Q10 in Retinal Pathology.International journal of molecular sciences · 2023Review
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Citicoline/Coenzyme Q10/Vitamin B3 Fixed Combination Exerts Synergistic Protective Effects on Neuronal Cells Exposed to Oxidative Stress.Nutrients · 2022Article
- Understanding Neurodegeneration from a Clinical and Therapeutic Perspective in Early Diabetic Retinopathy.Nutrients · 2022Review
- Circulating micronutrients as protective factors for the retinal structure and vasculature: Mendelian randomization analyses.Advances in ophthalmology practice and researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOur aim was to evaluate the effects of 36 months of treatment with citicoline and vitamin B
methodsA prospective, randomized, interventional, monocentric, double-masked study was conducted. Twenty patients with DM1 were enrolled and randomly divided into two groups: the DC group (10 patients; mean age ± standard deviation 46.86 ± 8.78 years) in which one eye of each patient was treated with citicoline and vitamin B
resultsWith respect to baseline, after 36 months of follow-up, the mfERG RADs recorded in R1, R2, R3, and R1 + R2 + R3 were significantly increased (i.e., R1 + R2 + R3 RAD from 21.552 ± 2.522 nV/degree
conclusionsThis study indicates that patients with NPDR treated with citicoline and vitamin B
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.